Immune system activation by cisplatin and its analog 'poly-plat': An in vitro and in vivo study

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 93-99

  Muenchen, Heather J ^a   Aggarwal, Surinder K ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

'Poly plat'; Cisplatin; In vitro; In vivo; Interleukin 1 ; Macrophages; Nitric oxide

Indexed keywords

CISPLATIN; INTERLEUKIN 1ALPHA; NITRIC OXIDE; POLY PLAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; IMMUNE RESPONSE; IMMUNE SYSTEM; LYMPHOCYTE; LYSOSOME; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031888515     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00012     Document Type: Article

References (35)

1. Aggarwal B, Totpal K. Mechanisms of regulation of cell growth by cytokines of the immune system. In: Pasquier C, Olivier R, Auclair C, eds. Oxidative stress, cell activation and viral infection. Basel: Birkhauser Verlag 1994: 155.
2. Palma J, Aggarwal S. Cisplatin and carboplatin mediated activation of murine peritoneal macrophages in vitro: production of interleukin-1α and tumor necrosis factor-α. Anti-Cancer Drugs 1995; 6: 1.
3. Sodhi A, Singh S. Release of cytolytic factor(s) by murine macrophages in vitro on treatment with cisplatin. Int J Immunopharmacol 1986; 8: 701.
4. Leh F, Wolf W. Platinum complexes: a new class of antineoplastic agents. J Pharmacol Sci 1976; 65: 315.
5. Rosenburg B, VanCamp L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res 1970; 30: 1799.
6. Durant J. Cisplatin: a clinical overview. In: Prestayko A, Crooke S, Carter S, eds. Cisplatin: current status and new developments. New York: Academic Press 1980: 317.
7. Zwelling L, Kohn K. Mechanism of action of cis-dichlorodiammine platinum (II). Cancer Treat Rep 1979; 63: 1439.
8. Bahadur A, Sarna S, Sodhi A. Enhanced cell mediated immunity in mice after cisplatin treatment. Polish J Pharmac Pharmacy 1984; 36: 441.
9. Singh S, Sodhi A. Interaction between cisplatin treated macrophages and Dalton's lymphoma cells in vitro. Exp Cell Biol 1989; 56: 1.
10. Palma J, Aggarwal S, Jiwa A. Murine macrophage activation after cisplatin or carboplatin treatment. Anti-Cancer Drugs 1992, 3: 665.
11. Muenchen H, Aggarwal S, Misra H, Andrulis P. Enhanced immunostimulation by novel platinum anticancer agents. Anti-Cancer Drugs 1997; 8: 323.
12. Fiebig H, Dress M, Ruhnau T, Misra H, Andrulis P, Hendriks H. GB-21, a novel platinum complex with antitumor activity in human renal and mammary xenografts. Proc Am Ass Cancer Res 1996; 37: 297.
13. Kiernan J. Histological & histochemical methods. Oxford: Pergamon Press, 1990.
14. Ding A, Nathan C, Stuehr D. Release of reactive nitrogen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidences for independent production. J Immunol 1988; 141: 2407.
15. Hsu S, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABS) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577.
16. Adams D, Hamilton T. Activation of macrophages for tumor cell kill: effector mechanisms and regulation. In: Heppner GH, Fulton AM, eds. Macrophages and cancer. Boca Raton, FL: CRC Press 1988: 27.
17. Stewart C, Stevenson A, Hibbs J. Effector mechanisms for macrophage-induced cytostasis and cytolysis of tumor cells. In: Heppner GH, Fulton AM, eds. Macrophages and cancer. Boca Raton, FL: CRC Press 1988: 39.
18. Sodhi A, Singh S. Interaction between cisplatin treated macrophages and Dalton's lymphoma cells in vitro. Exp Cell Biol 1989; 56: 1.
19. Palma JP, Aggarwal SK. Cisplatin and carboplatin mediated release of cytolytic factors in murine peritoneal macrophages in vitro. Anti-Cancer Drugs 1994; 5: 615.
20. Lachman L, et al. Natural and recombinant interleukin-1β is cytocidal for human melanoma cells. J Immunol 1986; 136: 3098.
21. Okubo A, Sone S, Tanaka M, et al. Membrane associated interleukin-1α as a mediator of tumor cell killing by human blood monocytes fixed with paraformaldehyde. Cancer Res 1989; 49: 256.
22. Gery I, Waksman B. Potentiation of cultured mouse thymocyte response by factors released by peripheral leukocytes. J Immunology 1986; 107: 1778.
23. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 1986; 137: 3295.
24. Kharazmi A, Neilson H, Bendtzen K. Recombinant interleukin-1α and β prime human monocytes superoxide but have no effect on chemotaxis and oxidative burst response of neutrophils. Immunobiology 1988; 177: 32.
25. Arouma O, Halliwell B, Dizdaroglu M. Iron ion dependent modification of bases in DNA by superoxide radical generating system hypoxanthine oxidase. J Biol Chem 1989; 264: 13024.
26. Richter C, Kass G. Oxidative stress in mitochondria: its relationship to cellular calcium homeostasis, cell death, proliferation and differentiation. Chem-Biol Interact 1991; 77: 1.
27. Chong Y, Heppner G, Paul L, et al. Macrophage mediated induction of DNA and breaks in target cells. Cancer Res 1989; 49: 6652.
28. Lowenstein C, Synder S. Nitric oxide, a novel biologic messenger. Cell 1992; 70: 705.
29. Moncada S, Palmer R, Higgs E. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109.
30. Esumi H, Tannenbaum S. Seminar on nitric oxide synthase and carcinogenesis. Cancer Res 1994; 54: 297.
31. Hibbs J, Taintor R, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deaminase and amino nitrogen oxidation to nitrite. Science 1984; 235: 473.
32. Stuer D, Nathan C. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543.
33. Krahenbuhl J, Remington J. The role of activated macrophages in specific and nonspecific cytostasis of tumor cells. J Immunol 1974; 113: 507.
34. Granger D, Lehninger A. Site of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol 1982; 95: 527.
35. Drapier J, Hibbs J. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfar enzymes in the macrophage effector cells. J Immunol 1988; 140: 2829.